Weed-Derived Secondary Metabolites in Polycystic Ovary Syndrome: Target Engagement, Exposure Plausibility and a Safety-Gated Framework for Candidate Prioritization
Background/Objectives: Existing PCOS reviews largely catalogue natural products and reported molecular pathways. This structured critical review asks a different translational question: which constituents from weed, ruderal and invasive taxa remain credible candidates when target engagement, pharmacological direction, realistic exposure and safety are considered together. Methods: PubMed/MEDLINE, Web of Science Core Collection and CAB Abstracts were searched from inception to 2 September 2026, with CABI resources used to verify weed status. Eligible pharmacological, pharmacokinetic and toxicological evidence was critically appraised using a T1–T4 mechanistic evidence hierarchy and evaluated for exposure plausibility, methodological quality and citation integrity. Results: No positive mechanistic claim reached T3 or T4. Urtica dioica L. lignans demonstrably displace dihydrotestosterone from SHBG in vitro, but the predicted consequence for free androgen exposure in vivo remains untested; flavonoid aromatase effects are assay- and context-dependent; and several widely cited systemic mechanisms are not supported by current exposure data. Silybin exposure supports a narrower liver-directed hypothesis, whereas non-absorbed inulin-type fructans provide a luminal gut-axis case in which systemic exposure is not required. Mentha spicata L. provides a reproducible human endocrine signal but no defined active constituent or molecular target. Conclusions: The principal barrier to clinical translation is not a shortage of activity signals but the absence of demonstrated in vivo target engagement, target-site pharmacokinetics and reproductive-safety qualification. No candidate currently clears all five gates. Silybum marianum flavonolignans and Cichorium intybus inulin-type fructans are therefore only provisionally prioritized for node-specific nonclinical development, while M. spicata is a mechanism-resolution research signal rather than a pharmacological lead. The framework prioritizes the experiments needed to establish development readiness; it does not infer PCOS-specific efficacy from the existing evidence.
Authors
- Pallav Sengupta (ORCID: https://orcid.org/0000-0002-1928-5048)
- Priyanshu Priya (ORCID: https://orcid.org/0000-0003-4918-0762)
- Sulagna Dutta (ORCID: https://orcid.org/0000-0002-7893-5282)
- Amit Mittal
- Motamarri V. N. L. Chaitanya
Institutions
- Lovely Professional University (IN)
- Gulf Medical University (AE)
- Ajman University (AE)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/ph19111816
- Primary Topic
- Ovarian function and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00